Insider trade

AbbVie (ABBV): Director received 155 units

Edward J Rapp, Director at AbbVie, reported a grant / award of 155 units.

155
Derivative units · @ $217.49
Traded
Mar 31, 2026
Filed
Apr 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
  2. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  3. Feb 19, 2026FDAFDA drug approval: Venclexta
  4. Feb 25, 2026Insider · Their largest sale since 2023Officer sold ~$5.15M of ABBV shares in the open market
  5. Mar 2, 2026Insider · 1 personInsiders: 3 sales (~$4.4M)
  6. Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
  7. Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
  8. Mar 6, 2026FDAFDA drug approval: Skyrizi
  9. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  10. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  11. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  12. Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000

What came next

  1. Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
  2. Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
  3. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  4. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  5. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  6. May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
  7. May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
  8. May 20, 2026FDAFDA drug approval: Venclexta
  9. May 21, 2026FDAFDA drug approval: Linzess
  10. May 27, 2026FDAFDA drug approval: Decnupaz
  11. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
  12. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  13. Jun 12, 2026FDAFDA drug approval: Skyrizi
  14. Jun 26, 2026FDAFDA drug approval: Skyrizi
  15. Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  16. Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
  17. Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
  18. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
  19. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
  20. Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

Explore the data

Common questions

Which AbbVie (ABBV) insider traded, and how much?

Edward J Rapp, Director at AbbVie, reported a grant / award of 155 units. At $217.49.

When did it happen, and when was it made public?

Traded: Mar 31, 2026. Filed: Apr 2, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data